Silencing FAT10 inhibits metastasis of osteosarcoma | Zendy

Chengbin Ma | Zendy; Zhiyu Zhang | Zendy; Yan Cui | Zendy; Hongmou Yuan | Zendy; Feng Wang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Silencing FAT10 inhibits metastasis of osteosarcoma

Author(s) -

Chengbin Ma,

Zhiyu Zhang,

Yan Cui,

Hongmou Yuan,

Feng Wang

Publication year - 2016

Publication title -

international journal of oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.405

H-Index - 122

ISSN - 1019-6439

DOI - 10.3892/ijo.2016.3549

Subject(s) - osteosarcoma , gene silencing , metastasis , oncogene , cancer research , molecular medicine , matrigel , biology , downregulation and upregulation , cancer , cell cycle , medicine , gene , angiogenesis , genetics

Metastasis is the main challenge of osteosarcoma treatment. Herein, we first reveal the oncogenic role of FAT10 in metastasis of osteosarcoma. FAT10 was upregulated in osteosarcoma, especially in metastatic osteosarcoma. High level of FAT10 was associated with poorer prognosis of osteosarcoma patients. Moreover, Transwell and Matrigel assays revealed that silencing FAT10 significantly inhibited the invasive and migratory abilities of osteosarcoma cells. Metastasis assay in vivo showed that silencing FAT10 decreased the number of mice with distant metastasis. We also found that FAT10 may act its oncogenic functions through regulating HOXB9. Collectively, the results suggested that FAT10 may be a novel therapeutic target for osteosarcoma patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research